J&J Exec On COVID-19 Vaccine: Moving At High Speed But No Safety Compromises
'Different Way Of Working'
J&J executive emphasizes that fast-tracked development of COVID-19 vaccines does not come with any corners cut around safety. Indian partner Biological E also outlines the complexities in manufacturing and believes that the candidates from J&J, AstraZeneca and others will be more suitable in profile and price terms to contain the pandemic globally.
